In fact, a recently published clinical case report showed that mesothelin-directed CAR T cells were able to mediate tumor regression in two patients; the first with malignant pleural mesothelioma and the second patients with pancreatic ductal adenocarcinoma [38]. This evidence concerns the gene MSLN and pancreatic ductal adenocarcinoma.